Updated 1/20/2026
| 340B ADR ID | Petitioner | Opposing Party | Allegation | Decision | Sanction |
|---|---|---|---|---|---|
| 240723-0024 | St. Croix Regional Medical Center (340B ID: CAH521337-00) | AstraZeneca (Labeler Codes: 00186 and 00310) | Overcharges | There is no overcharge violation in Petition ID 240723-0024, consistent with the rulings of the U.S. District Court for the District of Delaware and U.S. Court of Appeals for the Third Circuit with respect to AstraZeneca’s contract pharmacy policy. | None |
| 230925-19 | University of Washington Medical Center and Harborview Medical Center (340B IDs: DSH500008, DSH500064) | AstraZeneca (Labeler Codes: 00186 and 00310) | Overcharges | There is no overcharge violation in Petition ID 230925-19, consistent with the rulings of the U.S. District Court for the District of Delaware and U.S. Court of Appeals for the Third Circuit with respect to AstraZeneca’s contract pharmacy policy. Reconsideration was requested by petitioner. HRSA’s Reconsideration Official affirmed the ADR Panel’s decision. | None |
| 211115-11 | Emory University Hospital Midtown (340B ID: DSH110078) | Novartis Pharmaceuticals (Labeler code 00078) | Overcharges | There is no overcharge violation in Petition ID 211115-11, consistent with the rulings of the U.S. District Court for the District of Columbia’s and the U.S. Court of Appeals for the District of Columbia Circuit’s (D.C. Circuit) rulings with respect to Novartis’s contract pharmacy policy. | None |
| 231220-22 | University of Washington Medical Center and Harborview Medical Center (340B IDs: DSH500008, DSH500064) | Novo Nordisk (Labeler codes: 00169 and 73070) | Overcharges | There is no overcharge violation in Petition ID: 231220-22, consistent with the ruling of the U.S. Court of Appeals for the Third Circuit with respect to Novo Nordisk’s contract pharmacy policy. | None |
Date Last Reviewed: